18232, a novel dual specificity phosphatase and uses therefor
AssigneeMillennium Pharmaceuticals, Inc., a Delaware corporation
InventorsRachel A. Meyers, Nadine Weich
Life of this patent
Estimating the term…
Loading patent…
AssigneeMillennium Pharmaceuticals, Inc., a Delaware corporation
InventorsRachel A. Meyers, Nadine Weich
Estimating the term…
The invention provides isolated nucleic acids molecules, designated 18232 nucleic acid molecules, which encode novel dual specificity phosphatase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18232 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 18232 gene has been introduced or disrupted. The invention still further provides isolated 18232 proteins, fusion proteins, antigenic peptides and anti-18232 antibodies. Diagnostic methods utilizing compositions of the invention are also provided. The invention also provides methods of modulating the differentiation and proliferation of hematopoietic cells (e.g., erythroid cells) utilizing the compositions of the invention. Accordingly, methods of treating, preventing and/or diagnosing erythroid-associated disorders such as anemias, leukemias, and erythrocytosis are disclosed.
An isolated nucleic acid molecule selected from the group consisting of:
An isolated polypeptide selected from the group consisting of:
Dependencies are inferred from the claim text.